Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN – Research Report) and Adicet Bio (ACET – Research Report).
Terns Pharmaceuticals (TERN)
In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Terns Pharmaceuticals, with a price target of $17.00. The company’s shares closed last Tuesday at $3.55, close to its 52-week low of $3.26.
According to TipRanks.com, Tuerkcan is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Terns Pharmaceuticals with a $15.00 average price target.
See today’s best-performing stocks on TipRanks >>
Adicet Bio (ACET)
JMP Securities analyst Reni Benjamin reiterated a Hold rating on Adicet Bio today. The company’s shares closed last Tuesday at $1.18, close to its 52-week low of $1.10.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of
Adicet Bio has an analyst consensus of Moderate Buy, with a price target consensus of $17.67, a 1302.4% upside from current levels. In a report issued on November 9, JonesTrading also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TERN:
- Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals announces late-breaking data from Phase 2a DUET trial
- Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
